Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.99 USD
-0.04 (-4.17%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $1.00 +0.01 (1.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Adaptimmune Therapeutics PLC [ADAP]
Reports for Purchase
Showing records 1 - 20 ( 123 total )
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
3Q22: Lead Product''s Rolling BLA Submission Begins in December. Updated Responses in SURPASS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
3Q22: Lead Product''s Rolling BLA Submission Begins in December. Updated Responses in SURPASS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Ovarian Cancer Trial Posted on Clinicaltrials.gov
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SURPASS Data Support a Pipeline in a Product Against Solid Tumors--PT $10
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SURPASSing the Solid Tumor Challenge with the Second Gen TCR: Virtual Event During ESMO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
2Q22: Judicious Resource Allocation to Progress Platform. First Regulatory Submission in Q422
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T